Moleculin Biotech
MBRX
MBRX
23 hedge funds and large institutions have $4.32M invested in Moleculin Biotech in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Holders
23
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$40.9K | |
| 2 | +$19K | |
| 3 | +$16.4K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.17K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2K |
Top Sellers
| 1 | -$19K | |
| 2 | -$18.6K | |
| 3 | -$5.94K | |
| 4 |
SCM
Sio Capital Management
New York
|
-$5.44K |
| 5 |
JP Morgan Chase
New York
|
-$1K |